NAD代谢驱动人类和小鼠肠道炎症
本研究探讨烟酰胺磷酸核糖转移酶(NAMPT)抑制剂FK866在DSS结肠炎和AOM/DSS结肠炎相关癌症模型中的作用,并体外研究NAD耗竭对单核/巨噬细胞分化的影响。FK866减轻小鼠结肠炎、抑制炎症相关肿瘤发生,并有效抑制IBD患者固有层单核细胞因子释放,提示NAMPT阻断是急性肠道炎症的潜在治疗途径。
要点
- FK866抑制NAMPT降低黏膜NAD,减轻DSS诱导的小鼠结肠炎。
- FK866抑制AOM/DSS模型炎症相关肿瘤发生,并调节巨噬细胞极化。
- FK866有效抑制IBD患者固有层单核细胞的细胞因子释放。
核心结论
- 数据强调NAD免疫代谢对黏膜免疫的重要性,并突出FK866介导的NAMPT阻断作为急性肠道炎症有前景的治疗方法。
研究设计与样本
- 研究使用DSS结肠炎模型和AOM/DSS结肠炎相关癌症模型,并用体外实验研究NAD耗竭对小鼠和人类原代单核/巨噬细胞分化的影响。
- 最后在IBD患者固有层单核细胞中比较FK866与地塞米松和英夫利西单抗的疗效。
主要发现
- FK866改善DSS诱导的小鼠结肠炎,并抑制炎症相关肿瘤发生。
- FK866降低黏膜NAD,减少NAD依赖酶PARP1、Sirt6和CD38的丰度和活性,减少核因子κB激活,并减少炎症性单核细胞、巨噬细胞和活化T细胞的细胞浸润。
- FK866有效抑制IBD患者固有层单核细胞的细胞因子释放。
- FK866在Rag1-/-小鼠中也有效,机制上与单核/巨噬细胞生物学改变和巨噬细胞极化偏移相关:降低CD86、CD38、MHC-II和白细胞介素(IL)-6,促进CD206、Egr2和IL-10。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nicotinamide phosphoribosyltransferase (NAMPT, also referred to as pre-B cell colony-enhancing factor or visfatin) is critically required for the maintenance of cellular nicotinamide adenine dinucleotide (NAD) supply catalysing the rate-limiting step of the NAD salvage pathway. NAMPT is strongly upregulated in inflammation including IBD and counteracts an increased cellular NAD turnover mediated by NAD-depleting enzymes. These constitute an important mechanistic link between inflammatory, metabolic and transcriptional pathways and NAD metabolism. DESIGN: We investigated the impact of NAMPT inhibition by the small-molecule inhibitor FK866 in the dextran sulfate sodium (DSS) model of colitis and the azoxymethane/DSS model of colitis-associated cancer. The impact of NAD depletion on differentiation of mouse and human primary monocytes/macrophages was studied in vitro. Finally, we tested the efficacy of FK866 compared with dexamethasone and infliximab in lamina propria mononuclear cells (LPMNC) isolated from patients with IBD. RESULTS: FK866 ameliorated DSS-induced colitis and suppressed inflammation-associated tumorigenesis in mice. FK866 potently inhibited NAMPT activity as demonstrated by reduced mucosal NAD, resulting in reduced abundances and activities of NAD-dependent enzymes including PARP1, Sirt6 and CD38, reduced nuclear factor kappa B activation, and decreased cellular infiltration by inflammatory monocytes, macrophages and activated T cells. Remarkably, FK866 effectively supressed cytokine release from LPMNCs of patients with IBD. As FK866 was also effective in Rag1-⁄- mice, we mechanistically linked FK866 treatment with altered monocyte/macrophage biology and skewed macrophage polarisation by reducing CD86, CD38, MHC-II and interleukin (IL)-6 and promoting CD206, Egr2 and IL-10. CONCLUSION: Our data emphasise the importance of NAD immunometabolism for mucosal immunity and highlight FK866-mediated NAMPT blockade as a promising therapeutic approach in acute intestinal inflammation.
引用
- Gerner RR, Klepsch V, Macheiner S, et al. NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2017. PMID: 28877980. doi:10.1136/gutjnl-2017-314241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。